메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation

HONG KONG, Oct. 16, 2025 -- Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The study evaluated ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, combined with chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). The article of Lancet will be simultaneously published during the 2025 European Society for Medical Oncology (2025 ESMO) Congress. The HARM
- 김갑성 기자
- 2025-10-16 12:15
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs SAN DIEGO, Oct. 16, 2025 -- Illumina, Inc. (NASDAQ: ILMN) announced the release of its novel 5-base solution, enabling researchers to pursue broader biological questions with accuracy and ease. The 5-base solution marks a major advan
- 김갑성 기자
- 2025-10-16 11:43
ROSTI partners with IDC to bring innovative medical device design and manufacturing capabilities

SHANGHAI, Oct. 16, 2025 -- A report from Ringiertrade. MedTec China 2025, which took place at the Shanghai World Expo Exhibition & Convention Center (SWEECC) from September 24-26, served as the ideal platform to promote the latest innovations in the production of medical devices. At this exhibition, ROSTI Integrated Manufacturing Solutions (Suzhou) Co., Ltd. (ROSTI) provided visitors with interesting glimpse of its medical device design, assembly and production solutions aimed at the highly dynamic Asian markets. ROSTI, a pioneer injection molding and assembly for the medic
- 김갑성 기자
- 2025-10-16 11:30
Gene Solutions Brings Insights on Advances in MRD and Multi-Omics Technologies to the Singapore Society of Oncology Annual Scientific Meeting 2025

SINGAPORE, Oct. 15, 2025 -- What if cancer care could move from reactive to proactive? At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), Gene Solutions showcased how Molecular Residual Disease (MRD) and AI-powered multi-omics technologies are advancing precision oncology across Asia-Pacific, reinforcing Singapore's role as a hub for innovation and global collaboration. The symposium, "Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors," gathered leading oncologists and molecular biology experts to explore how ctDNA-MRD and mult
- 김갑성 기자
- 2025-10-16 10:30
DKSH Reinforces Patient-Centric Commitment with "Patient Purpose Day 2025", Spotlighting Women's Health Equity

DKSH Business Unit Healthcare continues bringing patient centricity to life with "Patient Purpose Day 2025". This global initiative, held for the third consecutive year across 12 markets across APAC and Switzerland, reinforces DKSH's dedication to improving patient outcomes. This year, the program focuses on advancing equity in women's health through meaningful community engagement and strategic partnerships. ZURICH, Oct. 16, 2025 -- DKSH Healthcare, the leading strategic healthcare business partner in Asia Pacific, launched its third annual "Patient Purpose Day
- 김갑성 기자
- 2025-10-16 10:00
시노케어, EASD에서 포괄적인 당뇨병 관리 솔루션 공개

빈 2025년 10월 16일 -- 유럽당뇨병학회(European Association for the Study of Diabetes, 이하 'EASD 2025') 제61회 연례회의가 오스트리아 빈에서 성공적으로 막을 내렸다. 이번 학회 기간 동안 시노케어(Sinocare)는 국제 산업 심포지엄과 독점 네트워킹 디너를 주최하며 당뇨병 관리 분야에서 자사의 우수한 전문성을 유감없이 보여줬다. 국제 전문가들, iCan CGM의 탁월한 임상 성과에 찬사 EASD 2025 개막일인 월요일 빈에서 열린 심포지엄에는 로리 라펠(Lori Laffel) 교수, 귀도 프레크만(Guido Freckmann) 박사, 줄리아 마더(Julia Mader) 교수가 초빙돼 iCanTM CGM과 협력한 연구 결과를 발표했다. 본 심포지엄은 '성능, 실용성, 소아과(Performance, Practicality, and Pediatrics)'를 핵심 주제를 다루면서, 최근 독일과 미국에서 성인과 소아 집단을 대상으로 진행된 연구에서 도출된 유망한 데이터를 발표했다. 또한 선도적인 소아 당뇨 센터에서 얻은 전문적 노하우를 토대로 실제 환경에서 CGM
- 김갑성 기자
- 2025-10-16 09:12
트라이넷엑스, 동료 심사 연구에서 가장 많이 인용된 실사용 데이터 출처로 부상

2000건 이상 인용•연간 80% 성장… 트라이넷엑스(TriNetX), 경쟁사 앞서며 주요 의학 저널의 과학 연구 뒷받침 케임브리지, 매사추세츠, 2025년 10월 15일 -- '연결된 세계'를 비전으로 인공지능과 데이터로 인간의 건강 향상을 이끄는 트라이넷엑스(TriNetX)가 동료 심사 학술지에서 가장 많이 인용된 전자건강기록(EHR) 데이터셋으로 자리매김했다. 이번 결과는 2025년 8월 27일 기준 PubMed 데이터를 분석한 최신 조사를 통해 확인됐다. 이번 분석에 따르면, 전 세계 임상 연구자, 공중보건 기관, 의료기관의 트라이넷엑스 데이터 사용이 급증했다. 총 2025건의 인용을 기록했으며, 이는 가장 가까운 경쟁사(149건)보다 약 1300% 높은 수치로, 실사용 증거(real-world evidence) 생성에 있어 트라이넷엑스의 역할이 빠르게 확대되고 있음을 보여준다. 연도별 인용 건수도 급격히 증가했다. 2021년 96건에서 2024년 707건으로 늘었으며, 2025년 1~8월 사이에만 952건이 인용됐다. 이러한 추세라면 트라이넷엑스는 올해 처음으로 연간 1000건 이상의 인용을 달성
- 김갑성 기자
- 2025-10-16 05:47
PENTAX Medical Announces Sale of C2 CryoBalloon™ Product Line to Merit Medical Systems through Asset Purchase Agreement

[ 메디채널 김갑성 기자 ] Transaction supports PENTAX Medical's strategic focus on core flexible reusable endoscopy MONTVALE, N.J., Oct. 16, 2025 -- PENTAX Medical, a division of HOYA Group and a global leader in flexible reusable endoscopy, today announced an asset purchase agreement with Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, for the acquisition of the C2 CryoBalloon™ technology. This strategic move allows PENTAX Medical to sharpen its focus on core endoscopic solutions while fostering deeper clinical partnerships. The C2 CryoBal
- 김갑성 기자
- 2025-10-16 04:05
Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline

BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry partner. Under the agreement, Oceanpine Capital will acquire 80% equity interest in Beijing Jacoray Pharmaceutical Technology Co., Ltd. ("Jacoray") for a total consideration of RMB 200 million (comprising RMB 125 million as the upfront payment and an additional RMB 75 million as a second instalment
- 김갑성 기자
- 2025-10-15 23:05
Advanced Instruments is Now Merged Under the Nova Biomedical Name: One Unified Brand Driving Innovation

WALTHAM, Mass., Oct. 15, 2025 -- We are proud to announce that Advanced Instruments and Nova Biomedical are now officially doing business under a single, unified brand. This is a transformative moment in our journey to deliver greater value to customers across the biopharmaceutical and clinical markets. Starting today we will be also unveiling a refreshed brand identity and logo across the merged organization that reflects our forward-looking vision and deep commitment to innovation. This strategic merger brings together two industry leaders with complementary strengths in anal
- 김갑성 기자
- 2025-10-15 22:36

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 18일 18시 00분